Novel approaches to whole sporozoite vaccination against malaria

Abstract The parasitic disease malaria threatens more than 3 billion people worldwide, resulting in more than 200 million clinical cases and almost 600,000 deaths annually. Vaccines remain crucial for prevention and ultimately eradication of infectious diseases and, for malaria, whole sporozoite bas...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 33; no. 52; pp. 7462 - 7468
Main Authors Bijker, Else M, Borrmann, Steffen, Kappe, Stefan H, Mordmüller, Benjamin, Sack, Brandon K, Khan, Shahid M
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 22.12.2015
Elsevier Limited
Subjects
Allergy and Immunology
Animals
Antimalarials - therapeutic use
Chemoprophylaxis
Chloroquine
Chloroquine - therapeutic use
Drug Evaluation, Preclinical
Genetic attenuation
Humans
Immunization
Liver stage
Malaria
Malaria - immunology
Malaria - prevention & control
Malaria Vaccines - genetics
Malaria Vaccines - immunology
Mice
Mosquitoes
Parasites
Plasmodium
Plasmodium - immunology
Plasmodium falciparum - genetics
Plasmodium falciparum - immunology
Pre-erythrocytic stages
Pre-Exposure Prophylaxis
Sporozoite
Sporozoites - immunology
Sporozoites - radiation effects
Vaccination - methods
Vaccine
Vaccines
Vaccines, Attenuated - immunology
Plasmodium
Immunization
Chemoprophylaxis
Malaria
Genetic attenuation
Chloroquine
Liver stage
Sporozoite
Vaccine
Pre-erythrocytic stages
Online AccessGet full text

Cover

More Information
Summary:Abstract The parasitic disease malaria threatens more than 3 billion people worldwide, resulting in more than 200 million clinical cases and almost 600,000 deaths annually. Vaccines remain crucial for prevention and ultimately eradication of infectious diseases and, for malaria, whole sporozoite based immunization has been shown to be the most effective in experimental settings. In addition to immunization with radiation-attenuated sporozoites, chemoprophylaxis and sporozoites (CPS) is a highly efficient strategy to induce sterile protection in humans. Genetically attenuated parasites (GAP) have demonstrated significant protection in rodent studies, and are now being advanced into clinical testing. This review describes the existing pre-clinical and clinical data on CPS and GAP, discusses recent developments and examines how to transform these immunization approaches into vaccine candidates for clinical development.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ObjectType-Article-1
ObjectType-Feature-2
Open Access provided for this article by the PATH Malaria Vaccine Initiative and ExxonMobil Foundation.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2015.09.095